牛乳杆菌 johnsonii通过恢复肠道屏障功能和减少NET介导的肠肝炎来缓解实验性结肠炎
Hao-Yu Liu1,2,3,4, Peng Yuan1,2,3,4, Shicheng Li1,2
1College of Animal Science and Technology, Yangzhou University, Yangzhou, PR China.
Communications biology
|August 14, 2025
概括
益生菌治疗 Lactobacillus johnsonii N5 通过加强肠道屏障和减少炎症,有效治疗炎症性肠病 (IBD). 它还可以预防和解决中性友好性炎症,显示出作为多面性IBD治疗的潜力.
科学领域:
- 胃肠病学 胃肠病学
- 微生物学 微生物学
- 免疫学 免疫学 免疫学
背景情况:
- 炎症性肠病 (IBD) 由于肠道屏障功能障碍,微生物失衡和免疫失调而构成全球健康挑战.
- 这些IBD机制之间的精确相互作用需要进一步阐明有效的治疗策略.
研究的目的:
- 为了研究Lactobacillus johnsonii N5的治疗潜力,在硫酸 (DSS) 诱导的大肠炎的小鼠模型中.
- 了解L. johnsonii N5对大肠炎产生影响的机制,包括屏障功能,炎症和微生物组成.
主要方法:
- 在DSS诱导的大肠炎小鼠模型中预防和治疗Lactobacillus johnsonii N5的使用.
- 评估临床大肠炎症状,结肠和血清炎症标志物,微生物多样性和粘膜完整性.
- 对中性粒细胞活动,凝血通路和中性粒细胞细胞外陷 (NET) 在结肠和肝脏中的形成进行分析.
主要成果:
- 预防性N5的使用缓解了结肠炎症状,减少了炎症标志物,并保持了微生物多样性和屏障完整性.
- 治疗N5减轻了疾病的进展,恢复了有益细菌,抑制了有害细菌,减少了细菌转移和全身炎症.
- 通过抑制凝血和NET形成,N5抑制了中性粒细胞介导的肠肝损伤,其作用部分由其代谢物介导.
结论:
- 牛乳杆菌 (Lactobacillus johnsonii N5) 在IBD治疗中发挥了双重作用:预防性屏障增强和治疗性炎症解决.
- N5有效降低中性恋炎症和相关的肠肝损伤,表明其作为IBD多方面的益生菌治疗的潜力.
更多相关视频
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
12.4K
06:24Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
Published on: October 13, 2023
1.1K
相关概念视频
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
324
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
324
01:29Inflammatory Bowel Disease IV: Pharmacological Management
189
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
189
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
420
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
420
01:29Drugs for Treatment of Ulcerative Colitis in IBD
237
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
237
01:30Inflammatory Bowel Disease II: Crohn's Disease
383
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
383
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271